proqolid

Home > Instruments > UCLA Prostate Cancer Index (UCLA-PCI)

INSTRUMENT DETAILS

UCLA Prostate Cancer Index (UCLA-PCI)

 
Developed in 1995
Includes the RAND 36-Item Health Survey v2 (SF-36 v2)
 

Author(s)

Litwin Mark S, MD, MPH; Brook Robert H, MD, ScD; Fink Arlene, PhD; Ganz Patricia A, MD; Hays Ron D, PhD; Leake Barbara, PhD

 

Purpose

  • Pathology:

Male genital diseases

Neoplasms

  • Disease:

Genital neoplasms, Male

[ prostate neoplasms ]

  • Objective:

To assess the impact of treatment for early stage prostate cancer on quality of life

  • Population for intended use:

Adult

Male

 
 

Characteristics

  • Type of instrument:

Health-Related Quality of Life - HRQL (incl. health status)

  • Administration mode:

Self-administered

  • Number of items:

20

  • Recall/Observation period:

During the past 4 weeks

 
 

Language(s)

  • Original language:

English for the USA

  • List of existing translations:

The translations listed below may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.
This list of translations is subject to constant changes, therefore please check the status of translations with MAPI Research Trust / the developers / copyright holders / distributors.

UCLA-PCI

Dutch for the Netherlands
French for France
Italian for Italy
Japanese for Japan
Spanish for Spain
 

Bibliographic reference(s) of the original questionnaire

 Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998 Jul;36(7):1002-12

Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995 Jan 11;273(2):129-35

Last update: April 2012

Last update in collaboration with the author: April 2008